Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 10, 2008. The report details a specific corporate action regarding the repurchase and cancellation of the company's own ordinary shares, executed under authority granted by shareholders at the Annual General Meeting on May 21, 2008.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 850,000 ordinary shares of 25 pence each.
- Purchase Price: 1,228.45 pence per share.
- Treasury Shares Held: 474,194,158 shares (representing 9.10% of total voting rights).
- Shares in Issue: 5,211,663,702 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the company's share capital through the cancellation of 850,000 repurchased shares. Consequently, the number of shares held in Treasury has increased to 474,194,158. The filing does not provide comparative data against prior periods for operational or financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total cost of the 850,000 share repurchase (850,000 shares x 1,228.45 pence).
- Confirm the updated total voting rights denominator (5,211,663,702 shares) for disclosure threshold calculations.
- Review the impact of the 9.10% Treasury share holding on future earnings per share (EPS) calculations.
- Check subsequent filings for the remaining balance of the share buyback program authorized on May 21, 2008.